PRECIPIO INC
PRPONASDAQTrading Snapshot
- Day Range
- $22.00 – $22.45
- 52-Week Range
- $13.80 – $33.63
- Volume
- $3.43B
- Avg Volume
- $4.00B
- Shares Outstanding
- 1.8M
- Next Earnings
- Oct 9, 2026
Fundamentals Snapshot
- Annual Revenue
- $24M
- Last Q Revenue
- $6M
- P/E Ratio
- —
- P/S Ratio
- 1.6x
- EPS (TTM)
- $-0.51
- Dividend Yield
- —
Why Investors Own PRPO
- ✓High-growth profile — revenue up +44.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 30% gross margin and 18% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About PRECIPIO INC
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Precipio Announces Q2-2026 Shareholder Update Call
Conference Call will be held on August 17th, 2026, at 5:00 PM EDTNEW HAVEN, Conn., July 31, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2026 shareholder update call on August 17th, 2026, at 5:00 PM ET. The call will include remarks on the company’s current core businesses, as well as a moderated live Q&A session at the end of the Company remarks. “We are excited to share our upcoming results for Q2. The team continues to mak
PRPO vs. NEO: Which Cancer Diagnostics Stock Is the Better Buy?
Precipio and NeoGenomics take different approaches to cancer diagnostics, but which oncology stock looks more compelling now? Let's dive in.